Cargando…
Ingredients of Huangqi decoction slow biliary fibrosis progression by inhibiting the activation of the transforming growth factor-beta signaling pathway
BACKGROUND: Huangqi decoction was first described in Prescriptions of the Bureau of Taiping People's Welfare Pharmacy in Song Dynasty (AD 1078), and it is an effective recipe that is usually used to treat consumptive disease, anorexia, and chronic liver diseases. Transforming growth factor beta...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419610/ https://www.ncbi.nlm.nih.gov/pubmed/22471627 http://dx.doi.org/10.1186/1472-6882-12-33 |
_version_ | 1782240742349996032 |
---|---|
author | Du, Jin-Xing Sun, Ming-Yu Du, Guang-Li Li, Feng-Hua Liu, Cheng Mu, Yong-Ping Chen, Gao-Feng Long, Ai-Hua Bian, Yan-Qin Liu, Jia Liu, Cheng-Hai Hu, Yi-Yang Xu, Lie-Ming Liu, Ping |
author_facet | Du, Jin-Xing Sun, Ming-Yu Du, Guang-Li Li, Feng-Hua Liu, Cheng Mu, Yong-Ping Chen, Gao-Feng Long, Ai-Hua Bian, Yan-Qin Liu, Jia Liu, Cheng-Hai Hu, Yi-Yang Xu, Lie-Ming Liu, Ping |
author_sort | Du, Jin-Xing |
collection | PubMed |
description | BACKGROUND: Huangqi decoction was first described in Prescriptions of the Bureau of Taiping People's Welfare Pharmacy in Song Dynasty (AD 1078), and it is an effective recipe that is usually used to treat consumptive disease, anorexia, and chronic liver diseases. Transforming growth factor beta 1 (TGFβ1) plays a key role in the progression of liver fibrosis, and Huangqi decoction and its ingredients (IHQD) markedly ameliorated hepatic fibrotic lesions induced by ligation of the common bile duct (BDL). However, the mechanism of IHQD on hepatic fibrotic lesions is not yet clear. The purpose of the present study is to elucidate the roles of TGFβ1 activation, Smad-signaling pathway, and extracellular signal-regulated kinase (ERK) in the pathogenesis of biliary fibrosis progression and the antifibrotic mechanism of IHQD. METHODS: A liver fibrosis model was induced by ligation of the common bile duct (BDL) in rats. Sham-operation was performed in control rats. The BDL rats were randomly divided into two groups: the BDL group and the IHQD group. IHQD was administrated intragastrically for 4 weeks. At the end of the fifth week after BDL, animals were sacrificed for sampling of blood serum and liver tissue. The effect of IHQD on the TGFβ1 signaling pathway was evaluated by western blotting and laser confocal microscopy. RESULTS: Decreased content of hepatic hydroxyproline and improved liver function and histopathology were observed in IHQD rats. Hepatocytes, cholangiocytes, and myofibroblasts in the cholestatic liver injury released TGFβ1, and activated TGFβ1 receptors can accelerate liver fibrosis. IHQD markedly inhibited the protein expression of TGFβ1, TGFβ1 receptors, Smad3, and p-ERK1/2 expression with no change of Smad7 expression. CONCLUSION: IHQD exert significant therapeutic effects on BDL-induced fibrosis in rats through inhibition of the activation of TGFβ1-Smad3 and TGFβ1-ERK1/2 signaling pathways. |
format | Online Article Text |
id | pubmed-3419610 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-34196102012-08-16 Ingredients of Huangqi decoction slow biliary fibrosis progression by inhibiting the activation of the transforming growth factor-beta signaling pathway Du, Jin-Xing Sun, Ming-Yu Du, Guang-Li Li, Feng-Hua Liu, Cheng Mu, Yong-Ping Chen, Gao-Feng Long, Ai-Hua Bian, Yan-Qin Liu, Jia Liu, Cheng-Hai Hu, Yi-Yang Xu, Lie-Ming Liu, Ping BMC Complement Altern Med Research Article BACKGROUND: Huangqi decoction was first described in Prescriptions of the Bureau of Taiping People's Welfare Pharmacy in Song Dynasty (AD 1078), and it is an effective recipe that is usually used to treat consumptive disease, anorexia, and chronic liver diseases. Transforming growth factor beta 1 (TGFβ1) plays a key role in the progression of liver fibrosis, and Huangqi decoction and its ingredients (IHQD) markedly ameliorated hepatic fibrotic lesions induced by ligation of the common bile duct (BDL). However, the mechanism of IHQD on hepatic fibrotic lesions is not yet clear. The purpose of the present study is to elucidate the roles of TGFβ1 activation, Smad-signaling pathway, and extracellular signal-regulated kinase (ERK) in the pathogenesis of biliary fibrosis progression and the antifibrotic mechanism of IHQD. METHODS: A liver fibrosis model was induced by ligation of the common bile duct (BDL) in rats. Sham-operation was performed in control rats. The BDL rats were randomly divided into two groups: the BDL group and the IHQD group. IHQD was administrated intragastrically for 4 weeks. At the end of the fifth week after BDL, animals were sacrificed for sampling of blood serum and liver tissue. The effect of IHQD on the TGFβ1 signaling pathway was evaluated by western blotting and laser confocal microscopy. RESULTS: Decreased content of hepatic hydroxyproline and improved liver function and histopathology were observed in IHQD rats. Hepatocytes, cholangiocytes, and myofibroblasts in the cholestatic liver injury released TGFβ1, and activated TGFβ1 receptors can accelerate liver fibrosis. IHQD markedly inhibited the protein expression of TGFβ1, TGFβ1 receptors, Smad3, and p-ERK1/2 expression with no change of Smad7 expression. CONCLUSION: IHQD exert significant therapeutic effects on BDL-induced fibrosis in rats through inhibition of the activation of TGFβ1-Smad3 and TGFβ1-ERK1/2 signaling pathways. BioMed Central 2012-04-03 /pmc/articles/PMC3419610/ /pubmed/22471627 http://dx.doi.org/10.1186/1472-6882-12-33 Text en Copyright ©2012 Du et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Du, Jin-Xing Sun, Ming-Yu Du, Guang-Li Li, Feng-Hua Liu, Cheng Mu, Yong-Ping Chen, Gao-Feng Long, Ai-Hua Bian, Yan-Qin Liu, Jia Liu, Cheng-Hai Hu, Yi-Yang Xu, Lie-Ming Liu, Ping Ingredients of Huangqi decoction slow biliary fibrosis progression by inhibiting the activation of the transforming growth factor-beta signaling pathway |
title | Ingredients of Huangqi decoction slow biliary fibrosis progression by inhibiting the activation of the transforming growth factor-beta signaling pathway |
title_full | Ingredients of Huangqi decoction slow biliary fibrosis progression by inhibiting the activation of the transforming growth factor-beta signaling pathway |
title_fullStr | Ingredients of Huangqi decoction slow biliary fibrosis progression by inhibiting the activation of the transforming growth factor-beta signaling pathway |
title_full_unstemmed | Ingredients of Huangqi decoction slow biliary fibrosis progression by inhibiting the activation of the transforming growth factor-beta signaling pathway |
title_short | Ingredients of Huangqi decoction slow biliary fibrosis progression by inhibiting the activation of the transforming growth factor-beta signaling pathway |
title_sort | ingredients of huangqi decoction slow biliary fibrosis progression by inhibiting the activation of the transforming growth factor-beta signaling pathway |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419610/ https://www.ncbi.nlm.nih.gov/pubmed/22471627 http://dx.doi.org/10.1186/1472-6882-12-33 |
work_keys_str_mv | AT dujinxing ingredientsofhuangqidecoctionslowbiliaryfibrosisprogressionbyinhibitingtheactivationofthetransforminggrowthfactorbetasignalingpathway AT sunmingyu ingredientsofhuangqidecoctionslowbiliaryfibrosisprogressionbyinhibitingtheactivationofthetransforminggrowthfactorbetasignalingpathway AT duguangli ingredientsofhuangqidecoctionslowbiliaryfibrosisprogressionbyinhibitingtheactivationofthetransforminggrowthfactorbetasignalingpathway AT lifenghua ingredientsofhuangqidecoctionslowbiliaryfibrosisprogressionbyinhibitingtheactivationofthetransforminggrowthfactorbetasignalingpathway AT liucheng ingredientsofhuangqidecoctionslowbiliaryfibrosisprogressionbyinhibitingtheactivationofthetransforminggrowthfactorbetasignalingpathway AT muyongping ingredientsofhuangqidecoctionslowbiliaryfibrosisprogressionbyinhibitingtheactivationofthetransforminggrowthfactorbetasignalingpathway AT chengaofeng ingredientsofhuangqidecoctionslowbiliaryfibrosisprogressionbyinhibitingtheactivationofthetransforminggrowthfactorbetasignalingpathway AT longaihua ingredientsofhuangqidecoctionslowbiliaryfibrosisprogressionbyinhibitingtheactivationofthetransforminggrowthfactorbetasignalingpathway AT bianyanqin ingredientsofhuangqidecoctionslowbiliaryfibrosisprogressionbyinhibitingtheactivationofthetransforminggrowthfactorbetasignalingpathway AT liujia ingredientsofhuangqidecoctionslowbiliaryfibrosisprogressionbyinhibitingtheactivationofthetransforminggrowthfactorbetasignalingpathway AT liuchenghai ingredientsofhuangqidecoctionslowbiliaryfibrosisprogressionbyinhibitingtheactivationofthetransforminggrowthfactorbetasignalingpathway AT huyiyang ingredientsofhuangqidecoctionslowbiliaryfibrosisprogressionbyinhibitingtheactivationofthetransforminggrowthfactorbetasignalingpathway AT xulieming ingredientsofhuangqidecoctionslowbiliaryfibrosisprogressionbyinhibitingtheactivationofthetransforminggrowthfactorbetasignalingpathway AT liuping ingredientsofhuangqidecoctionslowbiliaryfibrosisprogressionbyinhibitingtheactivationofthetransforminggrowthfactorbetasignalingpathway |